Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia (RCC2)
Depression, Delirium, Seizures
About this trial
This is an interventional basic science trial for Depression focused on measuring Anesthesia, Electroconvulsive therapy, Delirium, Electroencephalography, Seizures, Depression, Ketamine, Etomidate, Physiological Effects of Drugs, Pharmacologic Actions, Confusion, Mental Disorders, Neurobehavioral Manifestations, Signs and Symptoms, Neurologic Manifestations, Cognitive Disorders
Eligibility Criteria
Inclusion Criteria:
- Treatment resistant depression requiring outpatient ECT
- Planned right unilateral ECT stimulation
- English speaking
- Able to provide written informed consent
Exclusion Criteria:
- Known brain lesion or neurological illness that causes cognitive impairment
- Schizophrenia
- Schizoaffective disorder
- Blindness or deafness or motor impediments that may impair performance for cognitive testing battery
- Inadequate ECT seizure duration with etomidate
Sites / Locations
- Washington University School of Medicine
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Sham Comparator
Etomidate + ECT
Ketamine + ECT
Ketamine alone
General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.